Wellington Management Group LLP Sells 6,232 Shares of Agenus Inc. (NASDAQ:AGEN)

Wellington Management Group LLP lessened its position in shares of Agenus Inc. (NASDAQ:AGEN) by 6.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 86,131 shares of the biotechnology company’s stock after selling 6,232 shares during the period. Wellington Management Group LLP owned approximately 0.37% of Agenus worth $472,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Agenus during the 2nd quarter worth $1,921,000. FMR LLC lifted its position in shares of Agenus by 47.1% during the 3rd quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after buying an additional 27,309 shares during the last quarter. Walleye Capital LLC acquired a new stake in Agenus in the third quarter valued at about $1,003,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Agenus in the second quarter valued at about $106,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Price Performance

Agenus stock opened at $2.83 on Friday. The business has a 50 day moving average of $3.67 and a 200-day moving average of $7.16. The company has a market capitalization of $66.39 million, a P/E ratio of -0.25 and a beta of 1.24. Agenus Inc. has a 1 year low of $2.50 and a 1 year high of $19.69.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Agenus presently has an average rating of “Hold” and an average target price of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.